NCT01396408

A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 137 (actual)
• Sponsor: Canadian Cancer Trials Group · Network
• Sex: All
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

This research is being done because there is no treatment that will cure this type of cancer. Although some types of chemotherapy can cause this cancer to shrink for a time, better options are needed.

Detailed description

The purpose of this study is to find out what effects the study drugs - sunitinib or temsirolimus - will have on this type of cancer. The study will begin by finding out if sunitinib can shrink the cancer. If sunitinib does not work, temsirolimus will be tested next.

Conditions

• Advanced Rare Tumours

Interventions

Type	Name	Description
DRUG	Sunitinib	50 mg PO daily for 28 days, q 6 weeks (1 cycle=6 weeks or 42 days)
DRUG	Temsirolimus	25 mg IV weekly (Days 1, 8, 15, 22, 29, 36), q 6 weeks (1 cycle=6 weeks or 42 days)

Timeline

• Start date: 2012-02-09
• Primary completion: 2015-07-06
• Completion: 2026-06-30
• First posted: 2011-07-18
• Last updated: 2026-03-27

Locations

17 sites across 1 country: Canada